13:05 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Dicerna's DCR-PHXC reduces urinary oxalate levels in Phase I

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) reported interim six-week data from the Phase I PHYOX trial showing that single subcutaneous doses of DCR-PHXC brought urinary oxalate levels into the normal or near-normal range in five of eight...
19:06 , Sep 7, 2018 |  BC Extra  |  Financial News

RNAi company Dicerna raises $100M follow-on

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.79 (14%) to $14.81 on Friday after raising $100 million via the sale of 7.7 million shares at $13.02 in a follow-on underwritten by Citigroup, Leerink, Stifel, H.C. Wainwright and...
23:19 , Apr 20, 2018 |  BC Extra  |  Company News

Dicerna, Alnylam settle RNAi dispute

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.82 (18%) to $12.01 Friday after the company said it had resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing....
16:55 , Jun 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Mouse studies suggest inhibiting LDHA on myeloid cells could help treat lung adenocarcinoma. In a mouse model of the disease, myeloid cell-specific knockout of LDHA decreased tumor size, expression of an angiogenesis...
07:00 , Aug 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lactate dehydrogenase A (LDHA)

Cancer INDICATION: Pancreatic cancer In vitro, cell culture and mouse studies identified an LDHA inhibitor that could help treat glycolysis-dependent pancreatic cancer. Screening of about two million compounds followed by structure-guided optimization of the top...
07:00 , Jul 30, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lactate dehydrogenase A (LDHA); TP53 induced glycolysis regulatory phosphatase (TIGAR)

Cancer INDICATION: Pancreatic cancer Mouse and patient sample studies suggest inhibiting LDHA , which is required for glycolysis, could help treat p53-mutant pancreatic cancers. Levels of the glycolytic regulator TIGAR were lower in human pancreatic...
07:00 , May 1, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Lactate dehydrogenase A (LDHA); K-Ras (KRAS); epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1) Mouse studies suggest inhibiting LDHA could...
07:00 , May 5, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer HER2 (EGFR2; ERBB2; neu); heat shock transcription factor 1 (HSF1); lactate dehydrogenase A (LDHA) Studies in mice and in...
07:00 , Apr 3, 2008 |  BC Innovations  |  Targets & Mechanisms

Hitting cancer's sweet spot

Two reports published back to back in...
07:00 , Apr 16, 2007 |  BioCentury  |  Strategy

Alexion's pricing rationale

At $389,000 per year, the cost of Alexion Pharmaceuticals Inc. 's Soliris eculizumab, newly approved for paroxysmal nocturnal hemoglobinuria, comes in at the high end of drugs for ultra-orphan diseases. Still, the company does not...